Increased Progesterone Receptor Expression in Benign Epithelium of BRCA1-Related Breast Cancers

The study of pathologically normal breast epithelium of BRCA mutation carriers may yield insights into the early natural history of breast tumorigenesis. Hormone receptor expression was assessed in 24 cases of invasive breast cancer associated with a mutation in BRCA1 (n = 15) or BRCA2 (n = 9) and in 39 sporadic cases matched for patient age and tumor hormone receptor status. Expression of progesterone receptor was significantly (P = 0.0003) more common in normal breast epithelium adjacent to invasive breast carcinoma in BRCA1-linked cases compared with sporadic cases. The wild-type BRCA allele was retained in normal epithelium of all cases tested. We conclude that deregulation of progesterone receptor expression, as a result of BRCA1 haploinsufficiency, may represent an early event in BRCA1-linked breast tumorigenesis.

[1]  Nilanjan Chatterjee,et al.  Estrogen Receptor Breast Cancer Phenotypes in the Surveillance, Epidemiology, and End Results Database , 2002, Breast Cancer Research and Treatment.

[2]  J. Russo,et al.  Pattern of distribution of cells positive for estrogen receptor α and progesterone receptor in relation to proliferating cells in the mammary gland , 1999, Breast Cancer Research and Treatment.

[3]  E. Anderson.  Progesterone receptors – animal models and cell signaling in breast cancer: The role of oestrogen and progesterone receptors in human mammary development and tumorigenesis , 2002, Breast Cancer Research.

[4]  G. Mills,et al.  Evidence of haplotype insufficiency in human cells containing a germline mutation in BRCA1 or BRCA2 , 2002, International journal of cancer.

[5]  M. Erdos,et al.  p300 Modulates the BRCA1 inhibition of estrogen receptor activity. , 2002, Cancer research.

[6]  W. Lee,et al.  BRCA1 mediates ligand-independent transcriptional repression of the estrogen receptor , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[7]  S. Fuqua,et al.  Histological and biological evolution of human premalignant breast disease. , 2001, Endocrine-related cancer.

[8]  N. Chatterjee,et al.  Tumor variants by hormone receptor expression in white patients with node-negative breast cancer from the surveillance, epidemiology, and end results database. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  R. Hruban,et al.  BRCA2 is inactivated late in the development of pancreatic intraepithelial neoplasia: evidence and implications. , 2000, The American journal of pathology.

[10]  M. Perricaudet,et al.  Gamma-rays-induced death of human cells carrying mutations of BRCA1 or BRCA2 , 1999, Oncogene.

[11]  J. Sloane,et al.  Estrogen receptor-positive proliferating cells in the normal and precancerous breast. , 1999, The American journal of pathology.

[12]  D. Trichopoulos,et al.  Low oestrogen receptor α expression in normal breast tissue underlies low breast cancer incidence in Japan , 1999, The Lancet.

[13]  J. Sloane,et al.  Oestrogen receptor expression in the normal and pre‐cancerous breast , 1999, The Journal of pathology.

[14]  M. Erdos,et al.  BRCA1 inhibition of estrogen receptor signaling in transfected cells. , 1999, Science.

[15]  Daniel Birnbaum,et al.  Steroid receptors in hereditary breast carcinomas associated with BRCA1 or BRCA2 mutations or unknown susceptibility genes , 1999, Cancer.

[16]  J. Peto,et al.  Predicted anti-oestrogen resistance in BRCA-associated familial breast cancers. , 1998, European journal of cancer.

[17]  M. Fernö,et al.  Steroid receptors in hereditary breast carcinomas associated with BRCA1 or BRCA2 mutations or unknown susceptibility genes , 1998, Cancer.

[18]  T. Powles,et al.  Hormone status of in-situ cancer in BRCA1 and BRCA2 mutation carriers , 1998, The Lancet.

[19]  L. Norton,et al.  BRCA-associated breast cancer: absence of a characteristic immunophenotype. , 1998, Cancer research.

[20]  J. Klijn,et al.  Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1 , 1998, The Lancet.

[21]  A. Howell,et al.  Dissociation between steroid receptor expression and cell proliferation in the human breast. , 1997, Cancer research.

[22]  Å. Borg,et al.  Tumour biological features of BRCA1-induced breast and ovarian cancer. , 1997, European journal of cancer.

[23]  E. McDermott,et al.  Hereditary breast cancer , 1997, The British journal of surgery.

[24]  M. Aickin,et al.  Adjusting for multiple testing when reporting research results: the Bonferroni vs Holm methods. , 1996, American journal of public health.

[25]  M. Rogers,et al.  Estrogen receptor expression of benign breast epithelium and its association with breast cancer. , 1994, Cancer research.

[26]  A. Howell,et al.  Oral contraceptive (OCP) use increases proliferation and decreases oestrogen receptor content of epithelial cells in the normal human breast , 1991, International journal of cancer.

[27]  R. Coombes,et al.  Breast Estrogen and Progesterone Receptors in the Normal Female Updated Version , 2006 .

[28]  O. Petersen,et al.  Frequency and distribution of estrogen receptor-positive cells in normal, nonlactating human breast tissue. , 1987, Cancer research.